• 5:00 PM - 6:30PM
  • https://us02web.zoom.us/meeting/register/tZYqfuGhqzsuEtGugxgdy8Z41Td_tZyc8w11
  • We have all experienced challenges, uncertainty, and change in the last eighteen months. But through all of these experiences, there has been tremendous opportunity for reflection and growth, both personally and professionally. Join the ChIPs NY Chapter for the first of a series of events focused on finding opportunity through change, where senior leaders will share insights from their years of experience and personal career journeys on how best to do so. This inaugural event will feature a fireside chat with Lindsay Androski, the Founder, President, and CEO of Roivant Social Ventures. There will also be ample opportunity to ask your own questions. 


    Bio:  Lindsay Androski is the founder, President and CEO of Roivant Social Ventures, a social impact organization that makes early stage investments & incubates biotechs focused on improving healthcare access and outcomes for underserved groups. Ms. Androski currently serves as President of Incubate, an advocacy organization that educates policymakers on the critical role of early-stage venture capital in biopharma.  She is also a member of the MIT board of trustees and sits on the MIT Visiting Committees for Sponsored Research, the Department of Biology, and the Department of Humanities.  


    A noted expert in the creation, launch & scaling of biotechs, Ms. Androski joined the founding team at Roivant Sciences to build and lead the team responsible for the in-license or acquisition of more than 30 pharmaceutical drug candidates, resulting in the launch of 16 biotechs, three of which went public. To date, these efforts have led to four approved drugs now available to patients: Myfembree (heavy menstrual bleeding / uterine fibroids), Orgovyx (prostate cancer),  Gemtesa (overactive bladder), and Rethymic (pediatric congenital athymia). In addition to her dealwork, Ms. Androski led hiring of CEOs and CMO’s, partnership efforts in Japan and China, alliance management across the Roivant family of companies, and the intellectual property team. 


    Ms. Androski previously joined the Department of Justice as one of the inaugural Assistant U.S. Attorneys in the newly-launched Cybercrime unit of the Eastern District of Virginia. As a federal prosecutor, Ms. Androski was involved in investigations and prosecutions of high-profile cybercrime and national security cases, including WikiLeaks/Assange/Manning, Edward Snowden, and MegaUpload/Kim Dotcom, was nominated several times for the highest award given by the Department of Justice, and received the highest awards given by Immigration and Customs Enforcement and Customs and Border Protection. She then took that expertise back to the private sector, launching and leading the Cyber and Data Security practice group at Irell & Manella LLP. She is admitted to practice law in the U.S. Supreme Court, the U.S. Courts of Appeals for the Federal and Fourth Circuits, and the courts of California, New York, and the District of Columbia. 


    Ms. Androski holds two BS degrees from the Massachusetts Institute of Technology (Biology and History), JD and MBA degrees from The University of Chicago, is a registered patent lawyer and a Chartered Financial Analyst. Her writings have been published in Nature Gene Therapy, the Harvard Journal of Law and Public Policy, the John Marshall Review of Intellectual Property Law, and the University of Chicago Legal Forum.